The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Consolidated net loss | -25,746 | -34,413 |
| Depreciation and amortization | 165 | 333 |
| Stock-based compensation | 1,307 | 2,483 |
| Accretion of discount of available-for-sale investment securities | 512 | 981 |
| Amortization of right-of-use assets | 224 | 437 |
| Other receivables | 544 | -1,238 |
| Prepaid expenses and other assets | -4,795 | -1,445 |
| Accounts payable and accrued expenses | 18 | 485 |
| Operating lease liability | -183 | -341 |
| Net cash used in operating activities | -20,476 | -29,314 |
| Purchases of property and equipment | 37 | 9 |
| Purchases of available-for-sale investment securities | 39,340 | 41,260 |
| Maturities of available-for-sale investment securities | 19,000 | 40,150 |
| Net cash (used in) provided by investing activities | -20,377 | -1,119 |
| Proceeds from issuance of common stock through option exercises | 0 | 19 |
| Proceeds from issuance of common stock through employee stock purchase plan | 0 | 79 |
| Proceeds from issuance of common stock from at-the-market offerings, net of offering costs | 29,753 | 36,691 |
| Principal paid on finance lease liabilities | 136 | 264 |
| Net cash provided by financing activities | 29,617 | 36,525 |
| Net change in cash, cash equivalents and restricted cash | -11,236 | 6,092 |
| Cash and cash equivalents at beginning of period | 14,006 | - |
| Cash and cash equivalents at end of period | 8,862 | - |
aTYR PHARMA INC (ATYR)
aTYR PHARMA INC (ATYR)